Global strategic insights - pharmaceuticals - Indalytics


Published on

Global Strategic Insights are manually curated Competitive Intelligence reports for CEOs and Company Heads — which help them track their competition in the Easiest and Shortest way possible.

Published in: Business, News & Politics
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Global strategic insights - pharmaceuticals - Indalytics

  1. 1. Global Strategic Insights — Pharmaceuticals December 2, 2013 © Indalytics Advisors Pvt. Ltd.
  2. 2. Global Strategic Insights — Pharmaceuticals — Sample T ABLE OF C ONTENTS Activities by Major Players New Investments in global pharmaceutical space Strategies Collaboration Regulatory News 1
  3. 3. Global Strategic Insights — Pharmaceuticals — Sample A CTIVITIES BY M AJOR P LAYERS N EW I NVESTMENTS IN GLOBAL PHARMACEUTICAL SPACE Cancer Research UK (CRUK) is planning to invest more than GBP100 million (US$163 million) across 15 research centers in the UK. The centers, as a part of CRUK’s objective of creating a nationwide network of research centers, will work in the field of conducting research and providing medical expertise to cancer patients across the UK. GlaxoSmithKline (GSK) is planning to invest approximately £25 million (US$41 million) in Scotland’s pharmaceutical market. The investment is aimed at starting production of four new pharmaceutical products at GSK’s facility in Montrose. The investment will further provide 25 new jobs for process technicians, engineers and chemists — taking the total of GSK workforce in Scotland to more than 750. S TRA TEGIES Swiss drugmaker Novartis AG, in order to improve shareholders’ value, and has started a US$5billion share buyback program. The company will be allocating capital for buyback over a two–year period, and will also be less involved in acquisitions. 2
  4. 4. Global Strategic Insights — Pharmaceuticals — Sample GlaxoSmithKline is reducing its stake in South Africa's Aspen Pharmacare. GSK will sell 28.2 million of its total 84.7 million shares in Aspen, for approximately ZAR7.06 billion (US$690 million). Post the sale, GSK will retain a seat in Aspen’s board, and will not go for any other sale for a period of six months from completion of sale. It will use the sale proceeds for general corporate purposes. C OLLABORATION GlaxoSmithKline is collaborating with Pfizer to jointly test a combination of their respective melanoma compounds. As per the collaboration, the companies will jointly test the efficacy and safety of Pfizer's investigational drug palbociclib, a well as GlaxoSmithKline's Mekinist (trametinib) — which is already in the market. The joint trials will also ascertain the effect of trying both the medicines on tumor biomarkers, safety and anti-cancer activity in patients with BRAFV600 wild type melanoma. The two companies will collaborate on the study, which GSK will conduct. Financial terms of the agreement have not been disclosed. Dutch multinational Royal DSM, is pinning off its pharmaceuticals division, and collaborating with US private equity firm JLL Partners to setup a new company. As per the collaboration, the new entity will have Royal DSM’s Pharmaceutical Products division (DPP), along with the service company — Patheon — from JLL’s portfolio. The company will work as a global contract development and manufacturing organization (CDMO) for the 3
  5. 5. Global Strategic Insights — Pharmaceuticals — Sample pharmaceutical industry. JLL will have 51% stake in the new company, with 49% stake with Royal DSM. R EGULATORY N EWS Nexavar (Sorafenib) — a cancer drug co–developed and co–marketed by Bayer and Onyx Pharmaceuticals — has receive approval from the US Food and Drug Administration (FDA). As per the approval, Nexavar can now be used for the treatment of metastatic differentiated thyroid carcinoma that cannot be treated with radioactive iodine and is progressing. The approval was based on a review by FDA that Nexavar extended progression–free survival by 41%, compared to placebo. FDA is also removing certain restrictions from GlaxoSmithKline's diabetes drug — Avandia (rosiglitazone). The drug was linked to cardiovascular problems through a meta–analysis in 2007, and was banned in both the US and Europe. FDA has now acted on results of a record trial, which depicted that patients treated with Avandia, do not have increased risk of heart attack or death, as compared to those treated with metformin and sulphonylurea. 4
  6. 6. Global Strategic Insights — Pharmaceuticals — Sample W HAT IS G LOBAL S TRATEGIC I NSIGHTS ? At Agmaa, we have worked with many of the Fortune 500 executives, and have identified the following common concerns with them: 92% of the CEOs and company heads don’t’ have time to update themselves with latest activities of their competitors. 80% of the CEOs and company heads have less than 15 minutes every week, to track their respective sectors. 75% of the CEOs and company heads need ready–to–consume updates on their competitors and their sector, right before their meetings and presentations. 5
  7. 7. Global Strategic Insights — Pharmaceuticals — Sample Based on the client feedback and our extensive experience, we have designed Global Strategic Insights as an easy–to–decipher report. The competitive intelligence report helps our readers with: The report is written specifically for CEOs and company heads — to help them take accurate and timely decisions, and not miss– out on any trend. Each competitor news is manually curated — to be communicate in less than 100 words. The whole report can be read in less than 10 minutes. The activities are clubbed under trends — to help readers easily assimilate and recall them. The reports are published as PDF — to enable easy storage. In order to subscribe to Global Strategic Insights, please visit or mail us at 6